药明康德_业绩回顾_2025 年三季度业绩略超高盛预期；因订单势头强劲上调全年营收指引

Earnings Review: 3Q25 earnings slightly ahead of GSe; full-year revenue guidance raised on robust order momentum 29 October 2025 | 6:52PM HKT Equity Research Pharmaron (3759.HK) BUY | 3759.HK | 12m Price Target: HK$30.00 | Price: HK$24.96 | Upside: 20.2% | | --- | --- | --- | --- | | 300759.SZ | 12m Price Target: Rmb38.50 | Price: Rmb31.97 | Upside: 20.4% | Pharmaron reported 3Q25 revenue of Rmb3.65bn, up +13.4% y/y and +9.1% q/q, marginally above GSe of Rmb3.48bn. The topline was driven by sustained moment ...